- Home
- RVPHW vs PRDO Comparison
RVPHW vs PRDO Comparison
Compare RVPHW & PRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- PRDO
- Stock Information
- Founded
- RVPHW 2018
- PRDO 1994
- Country
- RVPHW United States
- PRDO United States
- Employees
- RVPHW 14
- PRDO N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- PRDO Other Consumer Services
- Sector
- RVPHW Health Care
- PRDO Real Estate
- Exchange
- RVPHW Nasdaq
- PRDO Nasdaq
- Market Cap
- RVPHW N/A
- PRDO N/A
- IPO Year
- RVPHW N/A
- PRDO N/A
- Fundamental
- Price
- RVPHW $0.03
- PRDO $32.02
- Analyst Decision
- RVPHW
- PRDO Buy
- Analyst Count
- RVPHW 0
- PRDO 1
- Target Price
- RVPHW N/A
- PRDO $40.00
- AVG Volume (30 Days)
- RVPHW 22.4K
- PRDO 634.9K
- Earning Date
- RVPHW 03-14-2025
- PRDO 07-30-2025
- Dividend Yield
- RVPHW N/A
- PRDO 1.62%
- EPS Growth
- RVPHW N/A
- PRDO N/A
- EPS
- RVPHW N/A
- PRDO 2.25
- Revenue
- RVPHW N/A
- PRDO $726,003,000.00
- Revenue This Year
- RVPHW N/A
- PRDO $24.62
- Revenue Next Year
- RVPHW N/A
- PRDO $3.83
- P/E Ratio
- RVPHW N/A
- PRDO $14.23
- Revenue Growth
- RVPHW N/A
- PRDO 6.35
- 52 Week Low
- RVPHW $0.13
- PRDO $20.55
- 52 Week High
- RVPHW $0.15
- PRDO $34.60
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- PRDO 50.27
- Support Level
- RVPHW N/A
- PRDO $31.72
- Resistance Level
- RVPHW N/A
- PRDO $33.17
- Average True Range (ATR)
- RVPHW 0.00
- PRDO 0.87
- MACD
- RVPHW 0.00
- PRDO -0.17
- Stochastic Oscillator
- RVPHW 0.00
- PRDO 42.28
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.